STOCK TITAN

Quest Diagnostics Inc - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.

Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.

Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.

Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.

Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) reported its Q1 2021 financial results, showcasing a remarkable recovery with net revenues reaching $2.72 billion, a 49.3% increase year-over-year. The diagnostic services segment contributed $2.64 billion, reflecting a 51.5% growth. Key metrics included a 375.8% surge in diluted EPS to $3.46 and operating income of $660 million, representing a 277.2% increase. The company also announced an accelerated share repurchase plan worth $1.5 billion, indicating strong cash flow and operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
buyback earnings
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) and Blueprint Genetics are presenting findings at the 2021 ACMG Annual Meeting, showcasing 10 studies on genomic sequencing's role in diagnosing inherited disorders. Notable research includes mitochondrial genome analysis improving diagnosis rates, especially in mitochondrial diseases, and next-generation sequencing (NGS) techniques enhancing hearing loss testing accuracy. These advancements exemplify the collaboration's commitment to improving patient care through innovative diagnostics and broadened access to genetic insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) will report its first quarter 2021 financial results on April 22, 2021, before markets open. The company will host a conference call at 8:30 a.m. Eastern Time to discuss these results. Interested participants can join by calling 888-455-0391 in the U.S. or 773-756-0467 internationally, using passcode '7895081.' A replay will be available online and via phone after the call. Quest Diagnostics continues to lead in diagnostic information services, impacting healthcare management for millions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) has announced the sale of its minority share in Q2 Solutions to IQVIA (NYSE: IQV) for $760 million in cash. This divestiture aligns with Quest's strategy to focus on diagnostic information services. Since 2015, Q2 Solutions operated as a joint venture, with IQVIA owning 60% and Quest 40%. Despite the sale, Quest will remain the preferred laboratory provider for Q2 Solutions under a multi-year agreement, allowing them to continue offering complementary lab testing services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
Rhea-AI Summary

On March 15, 2021, Zora Biosciences Oy announced a license agreement with Quest Diagnostics (NYSE: DGX) for its ceramide-analysis technology. This collaboration aims to develop a test service to identify patients at risk for cardiovascular diseases. Ceramides may indicate cardiovascular death risk, enhancing diagnostic precision beyond LDL cholesterol levels. Quest plans to offer this service through its Cardiometabolic Center of Excellence in the U.S. next year, aiming to alleviate heart disease burdens, which affect nearly half of the American population by 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) outlined its growth strategy at a recent virtual Investor Day, highlighting its responsiveness during the COVID-19 pandemic. The company reports a long-term revenue CAGR of 4-5% for its base business and 7-9% for total earnings. Key initiatives include increasing market share in advanced diagnostics and consumer testing, as well as capital investments of $900 million in share repurchases in 2021. The net revenue forecast for the first half of 2021 ranges from $4.85 billion to $5.15 billion, with a projected net revenue increase of 32.9% to 41.1%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
none
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) has entered into an all-cash agreement to acquire Mercy's outreach laboratory services business. This transaction, expected to complete in Q2 2021, aims to enhance access to innovative lab services across Arkansas, Kansas, Missouri, and Oklahoma. Mercy will retain its hospital laboratories for inpatient care, while Quest will integrate outreach tests into its network. The partnership prioritizes affordable patient care, leveraging Quest's advanced testing capabilities, patient service centers, and competitive pricing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
-
Rhea-AI Summary

Genalyte and Sonora Quest Laboratories have announced a strategic partnership with Cigna Medicare Arizona to enhance health outcomes using predictive analytics. This collaboration aims to reduce costs while improving care for patients enrolled in Cigna's Medicare Advantage plans. Through Genalyte's analytic models, healthcare providers can identify patients needing clinical oversight, enabling timely interventions. Cigna's goal is to leverage advanced analytics to foster informed decision-making, ultimately driving better health outcomes for customers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) has launched a new COVID-19 semi-quantitative serology test. This service provides insights into an individual's immune response from prior SARS-CoV-2 infections or vaccinations, offering both positive/negative results and numerical data on antibody levels. With about 40% of COVID-19 cases being asymptomatic, this test can identify antibodies two weeks post-infection. The testing aims to enhance public health monitoring by contributing to herd immunity research. It's currently available through Quest's network of over 2,200 patient service centers in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
covid-19
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Stock Data

18.18B
111.14M
0.44%
93.75%
2.31%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS